Is 0Q1N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0Q1N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0Q1N ($26.35) is trading below our estimate of fair value ($82.54)
Significantly Below Fair Value: 0Q1N is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0Q1N?
Key metric: As 0Q1N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 0Q1N. This is calculated by dividing 0Q1N's market cap by their current
earnings.
What is 0Q1N's PE Ratio?
PE Ratio
34.1x
Earnings
US$4.27b
Market Cap
US$145.81b
0Q1N key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 0Q1N is expensive based on its Price-To-Earnings Ratio (34.1x) compared to the European Pharmaceuticals industry average (19.6x).
Price to Earnings Ratio vs Fair Ratio
What is 0Q1N's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
0Q1N PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
34.1x
Fair PE Ratio
37.6x
Price-To-Earnings vs Fair Ratio: 0Q1N is good value based on its Price-To-Earnings Ratio (34.1x) compared to the estimated Fair Price-To-Earnings Ratio (37.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst 0Q1N forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
US$26.35
US$32.60
+23.7%
14.0%
US$45.00
US$25.00
n/a
23
Dec ’25
US$26.15
US$32.66
+24.9%
13.8%
US$45.00
US$25.00
n/a
23
Nov ’25
US$28.55
US$33.41
+17.0%
13.1%
US$45.00
US$27.00
n/a
23
Oct ’25
US$28.70
US$33.56
+16.9%
13.4%
US$45.00
US$27.00
n/a
22
Sep ’25
US$28.90
US$33.23
+15.0%
13.0%
US$45.00
US$27.00
n/a
22
Aug ’25
US$30.40
US$32.87
+8.1%
13.8%
US$45.00
US$27.00
n/a
22
Jul ’25
US$28.30
US$31.92
+12.8%
15.1%
US$45.00
US$27.00
n/a
22
Jun ’25
US$28.90
US$31.92
+10.4%
15.1%
US$45.00
US$27.00
n/a
22
May ’25
US$26.50
US$31.62
+19.3%
15.4%
US$45.00
US$26.00
n/a
22
Apr ’25
US$27.80
US$32.70
+17.6%
18.6%
US$50.00
US$26.00
n/a
22
Mar ’25
US$26.60
US$32.71
+23.0%
18.4%
US$50.00
US$26.00
n/a
23
Feb ’25
US$26.80
US$33.00
+23.2%
19.3%
US$50.00
US$26.00
n/a
22
Jan ’25
US$28.70
US$33.05
+15.2%
19.9%
US$50.00
US$23.00
n/a
22
Dec ’24
US$29.10
US$40.41
+38.9%
23.1%
US$75.00
US$32.00
US$26.15
22
Nov ’24
US$30.70
US$40.91
+33.3%
22.4%
US$75.00
US$32.00
US$28.55
22
Oct ’24
US$32.90
US$44.41
+35.0%
21.3%
US$75.00
US$32.00
US$28.70
22
Sep ’24
US$35.90
US$44.27
+23.3%
21.0%
US$75.00
US$32.00
US$28.90
23
Aug ’24
US$36.30
US$45.69
+25.9%
19.9%
US$75.00
US$35.00
US$30.40
23
Jul ’24
US$36.30
US$46.31
+27.6%
19.2%
US$75.00
US$35.00
US$28.30
22
Jun ’24
US$38.00
US$46.68
+22.8%
18.8%
US$75.00
US$35.00
US$28.90
22
May ’24
US$38.80
US$49.09
+26.5%
16.1%
US$75.00
US$40.00
US$26.50
22
Apr ’24
US$40.44
US$50.50
+24.9%
16.0%
US$75.00
US$40.00
US$27.80
22
Mar ’24
US$40.49
US$51.35
+26.8%
15.3%
US$75.00
US$40.00
US$26.60
21
Feb ’24
US$43.70
US$51.59
+18.1%
15.1%
US$75.00
US$40.00
US$26.80
21
Jan ’24
US$51.09
US$54.49
+6.7%
12.3%
US$75.00
US$44.00
US$28.70
21
Dec ’23
US$50.52
US$53.78
+6.5%
12.6%
US$75.00
US$44.00
US$29.10
21
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.